

Specification

Amendment filed on 10/31/2003 - 4 pages

Amendments to the Specification:

In the Sequence Listing, replace the original sequence listing with the amended sequence listing submitted herewith.

At page 24, replace the paragraph beginning at line 1 with the following paragraph.

By a "DAF-3 polypeptide" is meant a polypeptide that complements (as defined above) a *C. elegans daf-3* mutation and/or that possesses at least 60% amino acid sequence identity to SEQ ID NO: 35, at least 38% amino acid sequence identity to SEQ ID NO: 36, at least 47% amino acid sequence identity to SEQ ID NO: 85, or a combination thereof. Preferably, a DAF-3 polypeptide includes a proline or a glycine at amino acid positions corresponding to *C. elegans daf-3* amino acids at positions 200 (proline) and/or 620 (glycine) in Fig. 12A, respectively, or a combination thereof. For example, the polypeptide may include a proline in the motif GRKGFPHV (SEQ ID NO: ~~200~~ 322) or a glycine in the motif RIXXIXXG (where X is any amino acid) (SEQ ID NO: ~~201~~ 323).

At page 43, replace the paragraph beginning at line 23 with the following paragraph.

Fig. 28 is a graph illustrating the homology of *C. elegans* insulin-like molecules (SEQ ID NOS:117-124) with human insulin (SEQ ID NO:125) and a consensus motif (SEQ ID NO:324).

At page 43, replace the paragraph beginning at line 3 with the following paragraph.

Fig. 21A (~~SEQ ID NOS:211-215~~) is an illustration showing that human FKHR (SEQ ID NO:57), FKHL1 (SEQ ID NO:330), and AFX (SEQ ID NO:331) are the closest relatives to DAF-16 (SEQ ID NO:45). Note that the differentially spliced DAF-15 forkhead domain (DAF-16b) (SEQ ID NO:329) is less homologous.